The climate may cool with September's advent, but the industry late last week was still expecting a blast of potentially hot autumnal news about Phase III trials of Genentech Inc.'s monoclonal antibody Avastin (bevacizumab) in combination with chemotherapy against breast cancer. (Bioworld Financial Watch)